Search Results - "Moulder, S."

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types by McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Lim, B., Ueno, N.T., Litton, J.K., Ferrarotto, R., Chang, J.T., Moulder, S.L., Lin, S.-Y.

“…High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential…”
Get full text

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer by Fujii, T., Kogawa, T., Dong, W., Sahin, A.A., Moulder, S., Litton, J.K., Tripathy, D., Iwamoto, T., Hunt, K.K., Pusztai, L., Lim, B., Shen, Y., Ueno, N.T.

“…Although 1% has been used as cut-off for estrogen receptor (ER) positivity, several studies have reported that tumors with ER < 1% have characteristics similar…”
Get full text

Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity by Reddy, S M, Barcenas, C H, Sinha, A K, Hsu, L, Moulder, S L, Tripathy, D, Hortobagyi, G N, Valero, V

“…Background: We counsel our triple-negative breast cancer (TNBC) patients that the risk of recurrence is highest in the first 5 years after diagnosis. However,…”
Get full text

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer by Liedtke, C., Broglio, K., Moulder, S., Hsu, L., Kau, S.-W., Symmans, W.F., Albarracin, C., Meric-Bernstam, F., Woodward, W., Theriault, R.L., Kiesel, L., Hortobagyi, G.N., Pusztai, L., Gonzalez-Angulo, A.M.

“…We evaluated discordance in expression measurements for estrogen receptor (ER), progesterone receptor (PR), and HER2 between primary and recurrent tumors in…”
Get full text

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases by Turner, N.C., Finn, R.S., Martin, M., Im, S.-A., DeMichele, A., Ettl, J., Diéras, V., Moulder, S., Lipatov, O., Colleoni, M., Cristofanilli, M., Lu, D.R., Mori, A., Giorgetti, C., Iyer, S., Bartlett, C. Huang, Gelmon, K.A.

“…This report assesses the efficacy and safety of palbociclib plus endocrine therapy (ET) in women with hormone receptor-positive, human epidermal growth factor…”
Get full text

Advances in the Treatment of Breast Cancer by Moulder, S, Hortobagyi, G N

“…Breast cancer is the most commonly diagnosed cancer in American women and is the second leading cause of cancer‐related deaths in this population. This review…”
Get full text

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer by Moulder, S., Helgason, T., Janku, F., Wheler, J., Moroney, J., Booser, D., Albarracin, C., Morrow, P.K., Atkins, J., Koenig, K., Gilcrease, M., Kurzrock, R.

“…Mesenchymal/metaplastic breast cancers (MpBCs) are often triple-negative (TNBC), and chemo-refractory, and can harbor phosphoinositide 3-kinase (PI3kinase)…”
Get full text

Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer by Falchook, G.S., Moulder, S.L., Wheler, J.J., Jiang, Y., Bastida, C.C., Kurzrock, R.

“…Preclinical data indicate that dual HER2 inhibition overcomes trastuzumab resistance and that use of an HER2 inhibitor with an anti-angiogenic agent may…”
Get full text

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors by Hong, D. S., Henary, H., Falchook, G. S., Naing, A., Fu, S., Moulder, S., Wheler, J. J., Tsimberidou, A., Durand, J. B., Khan, R., Yang, P., Johansen, M., Newman, R. A., Kurzrock, R.

“…Summary Background PBI-05204, a Nerium oleander extract (NOE) containing the cardiac glycoside oleandrin, inhibits the α-3 subunit of Na-K ATPase, as well as…”
Get full text

Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC) by Hall, C., Hess, K.R., Ravenberg, L., Clayborn, A., Rauch, G.M., Candelaria, R., Mittendorf, E.A., Moulder, S.L., Thompson, A., Lucci, A.

Get full text

Impact of Statin Use on Outcomes in Triple-Negative Breast Cancer by Shaitelman, S.F, Stauder, M.C, Allen, P.K, Reddy, S, Lakoski, S.G, Atkinson, B.J, Moulder, S, Reddy, J, Amaya, D, Guerra, W, Ueno, N.T, Caudle, A.S, Tereffe, W, Woodward, W.A

Get full text

Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC) by Litton, J.K., Moulder, S.L., Hess, K.R., Damodaran, S., Rauch, G.M., Candelaria, R., Adrada, B.E., Symmans, F., Murthy, R.K., Helgason, T., Clayborn, A., Prabhakaran, S., Valero, V., Thompson, A.M., Mittendorf, E.A.

Get full text

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity by Litton, J. K., Scoggins, M., Ramirez, D. L., Murthy, R. K., Whitman, G. J., Hess, K. R., Adrada, B. E., Moulder, S. L., Barcenas, C. H., Valero, V., Gomez, J. Schwartz, Mittendorf, E. A., Thompson, A., Helgason, T., Mills, G. B., Piwnica-Worms, H., Arun, B. K.

“…This study was undertaken to determine the feasibility of enrolling breast cancer patients on a single-agent-targeted therapy trial before neoadjuvant…”
Get full text

Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC) by Yam, C., Seth, S., Hess, K.R., Mittendorf, E.A., Murthy, R.K., Damodaran, S., Helgason, T., Huo, L., Thompson, A.M., Barton, M., Huang, M.L., Arribas, E.M., Lane, D.L., Rauch, G.M., Adrada, B.E., Gilcrease, M.Z., Chang, J.T., Moulder, S.L.

Get full text

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers by Dumbrava, E.E., Call, S.G., Huang, H.J., Stuckett, A.L., Madwani, K., Adat, A., Hong, D.S., Piha-Paul, S.A., Subbiah, V., Karp, D.D., Fu, S., Naing, A., Tsimberidou, A.M., Moulder, S.L., Koenig, K.H., Barcenas, C.H., Kee, B.K., Fogelman, D.R., Kopetz, E.S., Meric-Bernstam, F., Janku, F.

“…Oncogenic mutations in PIK3CA are prevalent in diverse cancers and can be targeted with inhibitors of the phosphoinositide-3-kinase/protein kinase B/mammalian…”
Get full text

Neoadjuvant treatment of breast cancer by Thompson, A M, Moulder-Thompson, S L

“…Neoadjuvant treatment of breast cancer has become established as the safe and often effective therapeutic approach of choice for larger primary and for locally…”
Get full text

1871 Inhibition of mTOR in combination with chemotherapy and angiogenic blockade shows activity in metaplastic breast cancer, an aggressive, chemo-refractory subtype of triple-negative breast cancer (TNBC) by Basho, R, Janku, F, Helgason, T, Gilcrease, M, Booser, D, Karp, D, Meric-Bernstam, F, Wheler, J, Valero, V, Albarracin, C, Litton, J, Chavez-MacGregor, M, Ibrahim, N, Murray, J, Koenig, K, Hong, D, Subbiah, V, Kurzrock, R, Moulder, S

Get full text

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience by Wheler, J.J., Tsimberidou, A.M., Hong, D.S., Naing, A., Falchook, G.S., Fu, S., Moulder, S., Stephen, B., Wen, S., Kurzrock, R.

“…This study assessed toxicity in advanced cancer patients treated in a phase I clinic that focuses on targeted agents. An analysis of database records of 1181…”
Get full text

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo by MOULDER, Stacy L, YAKES, F. Michael, MUTHUSWAMY, Senthil K, BIANCO, Roberto, SIMPSON, Jean F, ARTEAGA, Carlos L

“…Aberrrant signaling by the epidermal growth factor receptor [EGFR (HER1, erbB1)] and/or HER2/neu tyrosine kinases is present in a cohort of breast carcinomas…”
Get full text

Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast cancer by Moulder, S L, Craft, B S, Hortobagyi, G N

“…Although significant advances have been made in the treatment of breast cancer using chemotherapy, less than half of the patients treated for localized breast…”
Get more information